

Takahashi K, Uchida K, Yoshimura N, <u>Takahara S.</u> , Teraoka S, Teshima R, Cornu-Artis C, Kobayashi E	Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results.	Transplantation Research	2(1)	14	2013
Wada M, Nishi K, Nakamura M, Kudo H, Yamaki S, Sasaki H, Sato T, Fukuzawa T, Tanaka H, Kazama T, Amae S, Nio M.	Life-threatening risk factors and the role of intestinal transplantation in patients with intestinal failure.	Pediatr Surg Int.	29(11)	1115-8	2013
Shindoh J, Sugawara Y, Akamatsu N, Kaneko J, Tamura S Yatomi Y, Makuchi M, Kokudo N, Koike K.	Thrombotic Microangiopathy After Living-Donor Liver Transplantation	Am J Transplant.	12(3)	728-36	2012
Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Takazawa Y, Aoki T, Hasegawa K, Sakamoto Y, Koike K, Kokudo N.	Living-donor liver transplantation for autoimmune hepatitis and autoimmune hepatitis-primary biliary cirrhosis overlap syndrome.	Hepatology Research.	42	1016-1023	2012

Yamashiki N, Sugawara Y, Tamura S, Nakayama NOketani M, Umeshita K, Uemoto S, Moachida S, Tsubouchi H, Kokudo N.	Outcome after living donor liver transplantation for acute liverfailure in japan;results of a natopnwide survey.	Liver Transplantation	18(9)	1069-77	2012
Kawaguchi Y, Sugawara Y, Yamashiki N, Kaneko J, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, Nojiri K, Kokudo N.	Role of 6-month abstinence rule in living donor liver transplantation for patients with alcoholic liver disease.	Hepatology Research.	43(11)	1169-74	2013
Shindoh J, Sugawara Y, Tamura S, Kaneko J, Yamashiki N, Aoki T, Hasegawa K, Sakamoto Y, Kokudo N.	Living donor liver transplantation for patients immunized against human leukocyte antigen.	J Hepatobiliary Pancreat Sci.	20	279-285	2013
Tanaka T, Sugawara Y, Tamura S, Kaneko J, Takazawa Y, Aoki T, Hasegawa K, Sakamoto Y, Yamashiki N, Kokudo N	Living donor liver transplantation for nonalcoholic steatphatitis:a single center experience	Hepatology Research..			2013

Togashi J, Sugawara Y, Akamatsu N, Tamura S, Yamashiki N, Kaneko J, Sakamoto Y, Aoki T, Hasegawa K, Kokudo N.	Quality of life after adult living donor liver transplantation: A longitudinal prospective follow-up study.	Hepatology Research.	43(10)	1052–63	2013
Fukushima N, Ono M, Saito S, Saiki Y, Kunota S, Tanoue Y, Minami M, Konaka S,	Ashikari J E H Donor evaluation and management system (medical consultant system) in Japan: experience from 200 consecutive brain-dead organ donation.	Transplant Proc	45(4)	1327–30	2013
Fukushima N, Ono M, Saito S, Saiki Y, Kunota S, Tanoue Y, Minami M, Konaka S, Ashikari J	E H Japanese strategies for maximizing lung availabilities: Experience from 100 consecutive brain dead donors.	Transplant Proc	45(8)	2871–4.	2013

Fukushima N. E H Chapter	2: Donor Assessment and Management for Maximizing Organ Availability. Organ Donation and Organ Donors: Issues, Challenges and Perspectives. Organ donation and organ donors: Issues, challenges and prospectives. Edited Reza Saisi,	Nova Science Publishers.		13–32	2013
Konaka S Shimuzu S, Iizawa M, Ohkawara H, Kato O, Ashikari J., Fukushima N.	E H Current status of in-hospital donation coordinators:	Nationwide survey in Japan Transplant Proc	45 (4)	1295–1300	2013
Kikuchi M, Okuda Y, Ueda Y, Nishioka Y, Uesugi M, Hashimoto E, Takahashi T, Kawai T, Hashi S, Shinke H, Omura T, Yonezawa A, Ito T, Fujimoto Y, Kaido T, Chiba T, Uemoto S, Matsubara K,	Successful telaprevir treatment in combination of cyclosporine against recurrence of hepatitis C in the Japanese liver transplant patients.	<u>Biol Pharm Bull.</u>	37(3)	417–23	2013

<u>Ito T</u> , <u>Chen D</u> , <u>Chang CW</u> , <u>Kenmochi T</u> , <u>Saito T</u> , <u>Suzuki S</u> , <u>Takemoto JY</u> .	Mesobiliverdin IX α Enhances Rat Pancreatic Islet Yield and Function.	<u>Front Pharmacol.</u>	23;4	50	2013
<u>Date H</u> , Shiraishi T, Sugimoto S, Shoji T, Chen F, Hiratsuka M, Aoyama A, Sato M, Yamane M, Iwasaki A, Miyoshi S, Bando T, Oto T.	Outcome of living-donor lobar lung transplantation using a single donor.	J Thorac Cardiovasc Surg	144(3)	710–5	2012
<u>Nakajima D</u> , <u>Chen F</u> , <u>Okita K</u> , <u>Motoyama H</u> , <u>Hijiya K</u> , <u>Ohsumi A</u> , <u>sakamoto J</u> , <u>Yamada T</u> , <u>Sato M</u> , <u>Aoyama A</u> , <u>Bando T</u> , <u>Date H</u> .	Reconditioning lungs donated after cardiac death using short-term hypothermic machine perfusion.	Transplantation	94(10)	999–1004	2012
<u>Chen F</u> , <u>Kubo T</u> , <u>Yamada T</u> , <u>sato M</u> , <u>Aoyama A</u> , <u>Bando T</u> , <u>Date H</u> .	Adaptation over a wide range of donor graft lung size discrepancies in living-donor lobar lung transplantation.	Am J Transplant	13(5)	1336–42	2013

Motoyama H, Chen F, Ohsumi A, Hijiya K, Okita K, Nakajima D, Sakamoto J, Yamada T, Sato M, Aoyama A, bando T, <u>Date</u> <u>H.</u>	Protective effect of plasma in marginal donor lungs in an ex vivo lung perfusion model.	J Heart Lung Transplant	32(5)	505-10	2013
Mizobuchi T, Chen F, Yoshino I, Iwata T, Yoshida S, bando T, <u>Date</u> <u>H.</u>	Radiologic evaluation for volume and weight of remnant lung in living lung donors.	J Thorac Cardiovasc Surg	146(5)	1253-8	2013
Ohsumi A, Chen F, Sakamoto J, Nakajima D, Kobayashi M, Bando T, <u>Date</u> <u>H.</u>	Protective effect of surfactant inhalation against warm ischemic injury in an isolated rat lung ventilation model.	Plos One	8(8)	e72574	2013
Chen F, Oga T, Sakai H, Matsumoto I, Yamada T, Sato M, Aoyama A, Bnado T, Mishima M, Chin K, <u>Date</u> <u>H.</u>	A prospective study analyzing one-year multidimensional outcomes in living lung transplant donors.	Am J Transplant	13(11)	3003-9	2013

Ono M, Nishimura T, Kinoshita O, Shiga T, Kinugawa K , Nagai R, Kyo S	Improved survival in patients with continuous-flow ventricular assist device for bridge to heart transplantation.	Transplant Proc	45	2017–8	2013
Yamauchi H, Motomura N, Chung UI, Sata M, Takai D, Saito A, Ono M, Takamoto S	Growth- associated hyperphosphatemia in young recipients accelerates aortic allograft calcification in a rat model.	J Thorac Cardiovasc Surg	145	522–30	2013
Imamura T, Kinugawa K, Ono M, Kagami Y, Endo M, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Hatano M, Yao A, Kyo S, Komuro I	Everolimus-incorporated immunosuppressant strategy improves renal dysfunction while maintaining low rejection rates after heart transplantation in Japanese patients.	Int Heart J	54	222–227	2013
Matsushima H, Soyama A, Takatsuki M, Hidaka M, Muraoka I, Kuroki T, Eguchi S	The Outcomes of Patients with Severe Hyperbilirubinemia Following Living Donor Liver Transplantation	Dig Dis Sci	58 (5)	1410–4	2013

Matsuzaki T, Ichikawa T, Otani M, Akiyama M, Ozawa E, Miura S, Miyaaki H, Taura N, Hayashi T, Okudaira S, Takatsuki M, Isomoto H, Takeshima F, Eguchi S, Nakao K	The significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of HBV re-infection after liver transplantation	J Gastroenterol Hepatol	28(7)	1217-22	2013
Minami S, Sakimura C, Hayashida N, Yamanouchi K, Kuroki T, Eguchi S	Timing of drainage tube removal after thyroid surgery: a retrospective study	Surg Today	44(1)	137-41	2013
Muraoka I, Takatsuki M, Sakai Y, Tomonaga T, Soyama A, Hidaka M, Hishikawa Y, Koji T, Utoh R, Ohashi K, Okano T, Kanematsu T, Eguchi S	Transplanted fibroblast cell sheets promote migration of hepatic progenitor cells in the incised host liver in allogeneic rat model	J Tissue Eng Regen			2013

Morooka Y ¹ , Umeshita K, Taketomi A, Shirabe K, Maehara Y, Yamamoto M, Shimamura T, Oshita A, Kanno K, Ohdan H, Kawagishi N, Satomi S, Ogawa K, Hagiwara K, Nagano H.	Reliability and validity of a new living donor quality of life scale.	Surg Today	43	732-740	2013
Wakayama K ¹ , Kamiyama T, Yokoo H, Kakisaka T, Kamachi H, Tsuruga Y, Nakanishi K, Shimamura T, Todo S, Taketomi A.	Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava.	World J Surg Oncol.	11	259	2013
Shiho Kosaka, Makoto Tanaka, Tomoko Sakai,	Development of Self-Management Scale for Kidney Transplant Recipients, Including Management of Post-Transplantation Chronic Kidney Disease.	ISRN Transplantation	vol. 2013	1-7	2013

Y. Oshiro, K. Nakagawa, K. Hoshinaga,	A Japanese Multicenter Study of High-Dose Mizoribine Combined With Cyclosporine, Basiliximab, and Corticosteroid in Renal Transplantation (The Fourth Report),	TRANSPLANTATION PROCEEDINGS	45 (4)	1476–1480	2013
Kato K, <u>Taniguchi M,</u> Iwasaki Y, Sasahara K, Nagase A, Onodera K, Matsuda M, Higuchi M, Nakano M, Kobashi Y, Furukawa H	Central Venous Access via External Jugular Vein with CT-Venography Using a Multidetector Helical 16-Section CT.	J Invest Surg	27 (3)	176–82	2013
Kato K, <u>Taniguchi M,</u> Iwasaki Y, Sasahara K, Nagase A, Onodera K, Matsuda M, Higuchi M, Kobashi Y, Furukawa H.	Computed Tomography (CT) Venography Using a Multidetector CT Prior to the Percutaneous External Jugular Vein Approach for an Implantable Venous-Access Port.	Ann Surg Oncol.	21 (4)	1391–7	2013

Wakiya T, Sanada Y, Mizuta K, et al	A comparison of open surgery and endovascular intervention for hepatic artery complications after pediatric liver transplantation.	Transplant Proc.	45(1)	323-9	2013
Urahashi T, Ihara Y, Mizuta K, et al	Effect of repeat kasai hepatic portoenterostomy on pediatric live-donor liver graft for biliary atresia.	Exp Clin Transplant	11(3)	259-63	2013
Wakiya T, Urahashi T, Mizuta K, et al:	Decreased portal vein flow during Kawasaki disease in a liver transplant patient.	Pediatr Int.	55(5)	e119-22	2013
Sanada Y, Wakiya T, Mizuta K, et al	Risk factors and treatments for hepatic arterial complications in pediatric living donor liver transplantation.	J Hepatobiliary Pancreat Sci.			2013
Urahashi T, Mizuta K, Ihara Y, et al	Impact of Post-transplant Flow Cytometric Panel Reactive Antibodies on Late Onset Hepatic Venous Outflow Obstruction following Pediatric Living Donor Liver Transplantation.	Transpl Int.			2013

Mizuta K, Urahashi T, Ihara Y, et al	Varicella zoster virus disease after pediatric living donor liver transplantation: is it serious?	Transplant Proc	44(3)	780-3	2012
Mizuta K, Urahashi T, Ihara Y, et al	Living donor liver transplantation in children with cholestatic liver disease: a single-center experience.	Transplant Proc	44(2)	469-72	2012
Sanada Y, Mizuta K, Urahashi T, et al	The efficacy of measurement of the serum beta-D glucan in the patients with biliary atresia.	Pediatr Surg Int	28(10)	993-6	2012
Sanada Y, Mizuta K, Urahashi T, et al	Impact of endotoxin measured by an endotoxin activity assay during liver transplantation.	J Surg Res	180(2)	349-55	2012
Sanada Y, Mizuta K, Urahashi T, et al:	Role of apheresis and dialysis in pediatric living donor liver transplantation: a single center retrospective study.	Ther Apher Dial	16(4)	368-75	2012
Sanada Y, Mizuta K, Urahashi T, et al	Co-occurrence of nonanastomotic biliary stricture and acute cellular rejection in liver transplant.	Exp Clin Transplant	10(2)	176-9	2012

Sanada Y, Ushijima K, et al	Prediction of acute cellular rejection by peripheral blood eosinophilia in pediatric living donor liver transplantation.	Transplant Proc	44(5)	1341–5	2012
Yoshizumi T, Ikegami T, Bekki Y, Ninomiya M, Uchiyama H, Iguchi T, Yamashita Y, Kawanaka H, Shirabe K, Maehara Y.	Re-evaluation of predictive score for 6-month graft survival in living donor liver transplantation in modern era.	Liver Transpl	20(3)	323–32	2014
Yoshizumi T, Shirabe K, Ikegami T, Yamashita N, Mano Y, Yoshiya S, Matono R, Harimoto N, Uchiyama H, Toshima T, Maehara Y.	Decreased immunoglobulin G levels after living donor liver transplantation is a risk factor for bacterial infection and sepsis.	Transpl Infect Dis	16(2)	225–31	2014
Yoshizumi T, Ikegami T, Toshima T, Harimoto N, Uchiyama H, Soejima Y, Yamashita Y, Shirabe K, Maehara Y.	Two-step selection criteria for living donor liver transplantation in patients with hepatocellular carcinoma.	Transplant Proc,	45	3310–3	2013

<u>Yoshizumi T,</u> Shirabe K, Nakagawara H, Ikegami T, Harimoto N, Toshima T, Yamashita Y, Ikeda T, Soejima Y, Maehara Y.	Skeletal muscle area correlates with body surface area in healthy adults.	Hepatol Res.	44(3)	313–8	2013
<u>Yoshizumi T,</u> Ikegami T, Yoshiya S, Motomura T, Mano Y, Muto J, Ikeda T, Soejima Y, Shirabe K, Maehara Y	Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma.	Hepatol Res.	43(7)	709–16	2013
<u>Yoshizumi T,</u> Shirabe K, Ikegami T, Kayashima H, Yamahita N, Morita K, Masuda T, Hashimoto N, Taketomi A, Soejima Y, Maehara Y	Impact of human T-cell leukemia virus type 1 in living donor liver transplantation	Am J Transplant	12(6)	1479–85	2012

<u>Yoshizumi T,</u> Shirabe K, Ikegami T, Soejima Y, Maehara Y.	Female-to-Male Match Predicted Poor Survival Following Living Donor Liver Transplantation-Some Issues Needed to be Clarified.	Transplantation.	94 (6)	e36	2012
<u>Yoshizumi T,</u> Shirabe K, Taketomi A, Uchiyama H, Harada N, Ijichi H, Yoshimatsu M, Ikegami T, Soejima Y, Maehara Y.	Risk factors that increase Mortality after living donor liver transplantation.	Transplantation,	93	93-8	2012
<u>Yoshizumi T,</u> Shirabe K, Soejima Y, Taketomi A, Ikegami T, Uchiyama H, Harada N, Ijichi H, Maehara Y.	Living Donor Liver Transplantation in Patients who have received pre-transplant treatment for hepatocellular carcinoma.	Transplantation	91	e61-2	2011

Miyagawa S, Maeda A, Kawamura T, Ueno T, Usui N, Kondo S, Matsumoto S, Okitsu T, Goto M, Nagashima H.	A comparison of the main structures of N-glycans of porcine islets with those from humans.	Glycobiology	24(2)	125–38	2013
Maeda A, Kawamura T, Ueno T, Usui N, Eguchi H, Miyagawa S.	The suppression of inflammatory macrophage-mediated cytotoxicity and proinflammatory cytokine production by transgenic expression of HLA-E.	Transpl Immunol.	29(1–4)	76–81	2013
Ueno T, Wada M, Hoshino K, Uemoto S, Taguchi T, Furukawa H, Fukuzawa M.	Impact of pediatric intestinal transplantation on intestinal failure in Japan: findings based on the Japanese intestinal transplant registry.	Pediatr Surg Int.	29(10)	1065–70	2013

Maeda A, Ueno T, Nakatsu S, Wang D, Usui N, Takeishi S, Okitsu T, Goto M, Nagashima H, Miyagawa S.	A lectin microarray study of glycoantigens in neonatal porcine islet-like cell clusters.	J Surg Res	183(1)	412–8	2013
Miyagawa S, Maeda A, Takeishi S, Ueno T, Usui N, Matsumoto S, Okitsu T, Goto M, Nagashima H.	A lectin array analysis for wild-type and α -Gal-knockout pig islets versus healthy human islets.	Surg Today.	43(12)	1439–47	2013
Hiroyuki Morikawa, Shusuke Kitamura, Takayuki Kiriki, Shinpei Oyama, Takashi Shibata, Hiroyuki Baba, Takashi Kawai	"Effects of see-through head mounted display for viewing 3D contents on visual function",	The 4th International Conference on 3D Systems and Applications, DVD-ROM Proceedings,		204–208	2012

III. 研究成果の刊行物・別刷

Chapter 1

History of Marginal Donors in the World

Norihide Fukushima

1.1 Introduction

Cadaver organ transplantation was started with donation after cardiac death (DCD). As determination of brain death was not established until 1968, the first liver transplant by Starzl et al. [1] in 1963 and the first heart transplant by Barnard [2] in 1967 were performed with DCD donors whose organs were procured under cardiopulmonary support (CPB). After the Harvard ad hoc committee [3] published the Harvard criteria for brain death in June 1968, organ donation from brain-dead persons has become the main current of cadaver organ transplantation. However, in Japan, only uncontrolled DCD kidney transplantation has been done since the 1960s, because brain-dead organ transplantation was not permitted for a long time.

As organ transplantation rapidly increased and organ shortage became more remarkable, DCD have been widely introduced in the clinical practice and the use of organs, especially kidneys, from DCD donors has been reported in multiple series [4] since the late 1980s in the developed countries. At that time, controlled DCD was the main current. Therefore, organs were harvested after cardiac death induced by extubation of the donor.

As percutaneous cardiopulmonary support (PCPS) was introduced in the clinical settings in the late 1980s, uncontrolled DCD using PCPS was initiated in Spain [5]. In 2000, Steen et al. [6] started uncontrolled DCD lung transplantation in Sweden (Table 1.1).

N. Fukushima (✉)

Department of Therapeutics for End-Stage Organ Dysfunction, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan
e-mail: nori@surg1.med.osaka-u.ac.jp

Table 1.1 History of organ transplantation

	Animal experiment and xenotransplant	Clinical experiences in the world	Clinical experiences in Japan
1902	Ullmann (Austria): animal experiments of RTx		
1905	Carrel (USA): animal experiments of HTx and RTx		
1906	Jaboulay (France): renal xenograft (sheep and pigs)		
1910	Sainai (Kyoto University): animal experiments of RTx January 5 Unger: renal xenotransplant (primates)		
1923	Neuhof: renal xenotransplant (lambs)		
1933		April 3 Voronoy (Ukraine): DCD RTx	
1940s	Medawar (USA): elucidation of mechanism of rejection		
1952	Dausset (USA): elucidation of human leukocytes antigens		
1954		December 23 Merrill and Murray (USA): successful RTx between identical twins	
1956			Kusunoki, Inoue (Niigata University): living RTx
1959		January 24 Merrill and Murray (USA): successful allogeneic RTx	
1961		March Calne (UK), Murray (USA): use of azathioprine in RTx	
1962		April 6 Murray (USA): successful DCD RTx	
1963	Reemtsma (USA): renal xenotransplant (chimpanzees and baboons)	March 1 Starzl (USA): lung Tx from uncontrolled DCD donor using CPB June 3 Alexandre (Belgium): first RTx from brain-dead donor June 11 Hardy (USA): lung Tx from uncontrolled DCD donor	